Feasibility and Comparative Outcomes of 24-Week Abrocitinib Tapering in Moderate-to-Severe Atopic Dermatitis
Highlight
- Abrocitinib tapering over 24 weeks in moderate-to-severe atopic dermatitis (AD) patients is feasible, achieving 97.4% successful tapering rate.
- Two tapering regimens (dose reduction vs interval extension) showed good efficacy but interval extension had higher rates of strategy switching due to disease fluctuation.
- Tapering resulted in nearly 41% reduction in cumulative abrocitinib dose and significant cost savings while maintaining clinical response.
Study Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.